Cara Therapeutics Q1 loss widens but beats estimates
Cara Therapeutics Inc. (NASDAQ: CARA)Â reported a wider loss in the first quarter of 2019 due to higher costs and expenses....
Health Care
Earnings preview: ‘Joint’ venture with Altria to help Cronos Group in Q1
Come Thursday and Cronos Group (NASDAQ: CRON) officially kicks off another season of cannabis stock earnings. The Toronto-based marijuana firm...
MannKind posts narrower-than-expected Q1 loss
MannKind Corporation (NASDAQ: MNKD) reported a narrower loss in the first quarter of 2019 helped by higher total revenues. The...
Earnings: Array BioPharma reports upbeat Q3 results
Array BioPharma (NASDAQ: ARRY) reported a narrower-than-expected loss in the third quarter of 2019, sending its shares up 0.5% during...
Mylan reports Q1 earnings beat on weak revenues, confirms 2019 outlook
Mylan’s (MYL) stock plunged about 5% in the pre-market trading after the company’s revenues failed to meet estimates. However, adjusted...
Allergan beats estimates on Q1 results, raises full-year guidance
Allergan plc (NYSE: AGN) topped market forecasts on revenue and earnings for the first quarter of 2019. Despite the beat,...
Regeneron Q1 profit falls 4%, misses estimates
Regeneron Pharmaceuticals (NASDAQ: REGN) reported a 4% decline in earnings for the first quarter of 2019 due to higher costs...
GW Pharmaceuticals’ stock climbs on Q1 results beat
Medical marijuana company GW Pharmaceuticals (NASDAQ: GWPH) beat market expectations on revenue and earnings for the first quarter of 2019,...
Bausch Health’s stock gains on improved outlook
Bausch Health Companies Inc. (NYSE: BHC) missed revenue expectations for the first quarter of 2019 and did not provide a...
Earnings preview: What to expect when Allergan reports Q1 2019 earnings results
Allergan plc (NYSE: AGN) is scheduled to report earnings results for the first quarter of 2019 on Tuesday, May 7,...
Earnings preview: Regeneron set for a blockbuster quarter amid robust sales
Regeneron Pharmaceuticals (Nasdaq: REGN) will be reporting earnings for the first quarter Tuesday before the opening bell. Market watchers are...
Immunogen Inc (NASDAQ: IMGN) Q1 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q1 2019 earnings call dated May 03, 2019 Corporate Participants: Sarah Kiely — Director of Investor Relations Mark Enyedy — President and Chief...
Wall Street expects a revenue surge from GW Pharmaceuticals in Q1
Medical marijuana company GW Pharmaceuticals (NASDAQ: GWPH) is scheduled to report first-quarter 2019 earnings results on May 6, Monday, after...
Novo Nordisk’s (NYSE: NVO) profit declines 3% in Q1 2019
Denmark-based healthcare giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) reported its first quarter 2019 results today. Novo Nordisk’s profit dropped...
ImmunoGen reports 57% decline in Q1 revenue
ImmunoGen Inc (NASDAQ: IMGN) on Friday reported weaker-than-expected top line in Q1, as the biotech firm continued to burn money...
Gilead Sciences tops Q1 earnings estimate, reiterates full-year outlook
Shares of Gilead Sciences (NASDAQ: GILD) gained 1.2% after the biotechnology firm reported first-quarter earnings of $1.76 per share, surpassing...
Novavax beats Q1 revenue estimates while earnings come in line
Novavax Inc. (NASDAQ: NVAX) topped market estimates on revenue for the first quarter of 2019 while earnings matched expectations. Analysts...
ImmunoGen is cheap ahead of Q1 earnings, but is it worth?
ImmunoGen Inc (NASDAQ: IMGN) is one of the worst performing stocks out there, losing about 78% of its value over...
Earnings: Cigna posts upbeat Q1 results
Cigna Corp. (NYSE: CI) reported a 50% jump in earnings for the first quarter of 2019 as continued strong business...
Teva Pharma sinks on Q1 revenue miss amid generic competition; earnings beat
Drugmaker Teva Pharmaceutical (NYSE: TEVA) reported a decline in first-quarter adjusted earnings, owing to a 15% fall in revenues as...
Abiomed’s stock plunges to new 52-week low on Q4 revenue miss
Abiomed’s (NASDAQ: ABMD) stock plunged about 17% in the pre-market trading as the company failed to meet top-line estimates. It...